Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea.

Abstract

Clostridium difficile-associated diarrhea (CDAD) is the most common cause of healthcare-associated diarrhea. The current recommended treatment regimens of metronidazole and vancomycin have not changed in nearly 25 years. Fidaxomicin, an exceedingly narrow spectrum macrolide antibiotic, was recently approved for the treatment of CDAD. In phase III clinical trials, fidaxomicin was noninferior to vancomycin in achieving clinical cure of CDAD. Furthermore, fidaxomicin was associated with fewer recurrences of CDAD compared with vancomycin in clinical trials. These results, combined with the ease of administration and a good safety profile, make fidaxomicin an attractive treatment option for treating CDAD.

• Authors: Yoav Golan, Lauren Epstein
• Journal: Therapeutic advances in gastroenterology (Therap Adv Gastroenterol) Vol. 5 Issue 6 Pg. 395-402 (Nov 2012) ISSN: 1756-2848 [Electronic] England
• PMID: 23152733 (Publication Type: Journal Article)